Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04935931 · ClinicalTrials.gov registry record · Early Phase 1
Naltrexone Neuroimaging
A Early Phase 1 study, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
NCT04935931 is a Early Phase 1 study that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 13 participants.
The verdict
NCT04935931, a Early Phase 1 study, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this open-label, pilot study is to evaluate fMRI as a biomarker of opioid antagonism in adolescents with ED. Modulation of brain activation will be examined in regions of interest by fMRI using a food-specific and general reward task in adolescents with ED in a pre/post design.
Interventions
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2022-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04935931
The ClinicalTrials.gov registry entry for NCT04935931 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Naltrexone is the first listed.
NCT04935931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04935931 about?
NCT04935931 is a clinical study titled "Naltrexone Neuroimaging". The purpose of this open-label, pilot study is to evaluate fMRI as a biomarker of opioid antagonism in adolescents with ED. Modulation of brain activation will be examined in regions of interest by fMRI using a food-specific and general reward task in adolescents with ED in a pre/post design.
What is the current status of trial NCT04935931?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2021-07-16. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT04935931?
The interventions under investigation include: Naltrexone (DRUG).
Who is sponsoring clinical trial NCT04935931?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.